Bariatric SUrgery With Mesh REpair of Ventral Hernia: a Randomized Controlled Trial (BeSURE)

August 30, 2023 updated by: Assistance Publique - Hôpitaux de Paris

Bariatric Surgery With Mesh Repair of Ventral Hernia: a Randomized Controlled Trial

The primary objective of the study is to demonstrate that hernia recurrence (VH) repair with non absorbable mesh concomitant to Bariatric Surgery (BS) decreases the risk of VH, with or without surgical repair, during the first two years after BS when compared to VH suture repair without mesh.

As secondary objectives, the study aims to assess the impact of concomitant VH repair with non absorbable mesh versus suture repair in morbidly obese BS candidates on the following measures: - hernia recurrence at 1 year after randomization; - reoperation for hernia recurrence at 2 years after randomization; - strangulated hernia, surgical infection and mesh bulging at one year after randomization; - postoperative morbidity and mortality at 90 days after randomization; - benefit-risk ratio; - chronic pain at three months, six months, one year and two years after randomization; - quality of life during the two years after randomization; - incremental cost utility ratio; - short- and mid-term weight loss. To study if the efficacy of mesh versus suture VH repair differs according to the type and size of VH and to the surgical technique.

Study Overview

Status

Recruiting

Conditions

Detailed Description

This is a prospective, multicentric, superiority, comparative randomized (1:1) single-blinded clinical trial with blinded assessment of the primary endpoint.

Hypothesis for the study: abdominal ventral hernia (VH) repair with mesh during bariatric surgery (BS) is more effective than suture repair in preventing VH recurrence. Secondarily, we expect that mesh repair would not increase the risk of surgical site infection.

Population of study participants:

Patients between 18 and 60 years, presenting with VH and scheduled for BS, excluding pregnant women and protected adults.

All consecutive eligible patients will be invited to participate by visceral surgeons during preoperative consultations for BS. Included patients will be randomly assigned (1/1 ratio) to either mesh VH repair (intervention group) or suture VH repair (control group) by visceral surgeons at hospital admission (hospitalization or outpatient surgery) for BS and VH repair.

Patients will be followed according to clinical guidelines for BS follow-up at M1, M3, M6, M9, M12, M18 and M24 after BS.

There will be 29 surgical centers in France (digestive surgeons), targetting 354 eligible patients.

Statistical analysis:

An intention-to-treat statistical analysis will be performed at the end of the follow-up, when primary endpoint of all randomized patients will be documented.

The analysis for the primary endpoint will consist in comparing proportions of hernia recurrence during the two years after surgery between the two arms, using a Chi2 test.

An interim analysis is planned after half of the subjects finished their follow-up, in order to confirm the efficacy of the intervention arm, or alternatively its lack of efficacy.

Study Type

Interventional

Enrollment (Estimated)

354

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Colombes, France, 92025
        • Recruiting
        • Department of visceral and digestive surgery, Louis Mourier hospital, APHP

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients between 18 and 60 years.
  • Body Mass Index (BMI) ≥ 40 kg/m² or ≥ 35 kg/m² associated with at least one comorbidity that can improve after BS.
  • Body Mass Index (BMI) < 50 kg/m².
  • Primary or first recurrent incisional midline VH, umbilical or epigastric, width between 1 cm and 4 cm, on abdominopelvic CT-scan without contrast injection.
  • Decision for primary sleeve gastrectomy or by-pass after multidisciplinary discussion.
  • Request for BS approved by health insurance authorities.
  • Written informed consent from patient.

Exclusion Criteria:

  • Previous VH repair with mesh.
  • Other types of abdominal hernia (lateral, subxiphoidal, infraumbilical, suprapubic, parastomal, non-midline port-site, and groin hernia).
  • Decision of performing BS by laparotomy.
  • Reoperation for BS (excepted previous adjustable gastric banding).
  • Ongoing abdominal skin infection.
  • Emergency surgery.
  • ASA (American Society of Anesthesiologists) score>3.
  • Ongoing pregnancy or breast-feeding.
  • Patient not covered by social insurance.
  • Patient under legal guardianship.
  • Patient already included in a clinical trial on hernia recurrence.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Mesh group

ventral hernia repair with non absorbable mesh placement concomitant to bariatric procedure (sleeve gastrectomy or by-pass).

In this group, the repair technique and the type of mesh are left to the choice of the center, as there are no strong data to demonstrate which technique is the best for VH repair in this population.

Abdominal ventral hernia (VH) repair with mesh during bariatric surgery. the repair technique and the type of mesh are left to the choice of the center, as there are no strong data to demonstrate which technique is the best for VH repair in this population.
Active Comparator: Suture group

suture repair of ventral hernia concomitant to bariatric procedure (sleeve gastrectomy or by-pass).

In this group, the hernia sack is resected through an open approach, and the fascial defect is systematically closed with a slowly absorbable monofilament suture.

The hernia sack is resected through an open approach, and the fascial defect is systematically closed with a slowly absorbable monofilament suture.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hernia recurrence rate, with or without surgical repair
Time Frame: at 2 years

Final diagnosis of hernia recurrence will be made by an endpoint committee of radiologists, blinded to the randomization arm (it is not possible to distinguish mesh from suture repair on CT-scans) on abdomino-pelvic CT-scan without contrast injection.

Radiological hernia is defined as any protrusion of abdominal contents, including the anterior parietal peritoneum, visible as discontinuity of the fascial layers.

In case of hernia recurrence requiring new VH repair during the study period (before the two years CT-scan evaluation), this will be considered as an event in intention-to-treat analysis.

at 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hernia recurrence rate at 1 year
Time Frame: at 1 year
Hernia recurrence rate clinically
at 1 year
Reoperation rate for recurrence at 2 years
Time Frame: at 2 years
Reoperation rate for recurrence, at 2 years after randomization with medical files.
at 2 years
Strangulated hernia rate at 1 year
Time Frame: at 1 year
Strangulated hernia rate (requiring emergent surgery), at 1 year after randomization (medical files)
at 1 year
Surgical site infection rate at 1 year
Time Frame: at 1 year
Surgical site infection rate (superficial or deep), at 1 year after randomization (medical files)
at 1 year
Mesh bulging rate at 2 years
Time Frame: at 2 years
Mesh bulging rate, defined by a protrusion of the mesh through a fascial defect without hernia recurrence at CT-scan evaluation, at 2 years after randomization.
at 2 years
Postoperative morbidity rate
Time Frame: daily up to 90 days
Postoperative morbidity rate (any complication in the 90 days after randomization).
daily up to 90 days
Postoperative mortality rate
Time Frame: daily up to 90 days
Postoperative mortality rate (any complication in the 90 days after randomization).
daily up to 90 days
Benefit-risk ratio
Time Frame: at the end of the study
Benefit-risk ratio (DOOR-RADAR score established by the scientific committee prior to the start of the study).
at the end of the study
Self-reported chronic pain
Time Frame: at 3 months, 6 months, 1 year and 2 years
Self-reported chronic pain, using the Visual Analogue Scale, at 3 months, 6 months, 1 year and 2 years after randomization
at 3 months, 6 months, 1 year and 2 years
Score of quality of life
Time Frame: at 3 months, 6 months, 1 year and 2 years
Using the EQ-5D-5L self-questionnaire EuroQol-5Dimensions-5Levels self-questionnaire (EQ-5D-5L value : -0.530 to 1.0 ; 1.0 indicates the best quality of life)
at 3 months, 6 months, 1 year and 2 years
Pain evaluation
Time Frame: at 3 months, 6 months, 1 year and 2 years
Using Visual Analogue Scale Visual Analogue Scale (0 to100; 0 represents 'no pain at all' whereas 100 represents 'the worst pain ever possible')
at 3 months, 6 months, 1 year and 2 years
Incremental cost utility ratio
Time Frame: at 2 years
Cost will be calculated.
at 2 years
Weight loss
Time Frame: at 3 months, 6 months, 1 year and 2 years
Short-term weight loss (percentage of excess weight loss at 3 and 6 months after the procedure); mid-term weight loss (percentage of excess weight loss at 1 and 2 years after the procedure).
at 3 months, 6 months, 1 year and 2 years
Hernia recurrence rate at 2 years
Time Frame: at 2 years
Hernia recurrence rate at 2 years after randomization, by type (primary or incisional) and size of VH and by surgical technique (sublay/retromuscular or intraperitoneal or preperitoneal/underlay).
at 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: David MOSZKOWICZ, MD, PhD, Department of visceral and digestive surgery, Louis-Mourier hospital, APHP

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 24, 2023

Primary Completion (Estimated)

January 1, 2030

Study Completion (Estimated)

January 1, 2030

Study Registration Dates

First Submitted

July 28, 2022

First Submitted That Met QC Criteria

August 2, 2022

First Posted (Actual)

August 4, 2022

Study Record Updates

Last Update Posted (Actual)

August 31, 2023

Last Update Submitted That Met QC Criteria

August 30, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • APHP211049
  • 2023-A00658-37 (Registry Identifier: IDRCB)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ventral Hernia

Clinical Trials on Mesh repair

Subscribe